p-value Group has been acquired by Publicis Groupe
September 2025 — p-value Group, one of the largest independent medical communications agencies in North America, has been acquired by Publicis Groupe (ENXTPA:PUB) for its strong strategic fit, global scale and cultural alignment. The acquisition enhances Publicis Groupe’s medical communications capabilities in the USA and supports its broader strategy of integrating science-first solutions across its global network.
Founded in 2004 by Linda Corvari, p-value is a leading full-service provider of medical and scientific communications, serving marquee clients across the life sciences sector. The company specializes in medical strategy, scientific communications, content development and speaker bureau management, earning a strong reputation for scientific rigor, exceptional client service and a culture of excellence. p-value maintains diverse and expanding expertise across therapeutic areas, with particularly strong experience in dermatology.
Publicis Groupe, founded in 1926 and headquartered in Paris, France, is the world's second-largest advertising holding company by revenue. The group offers a broad range of services, including traditional and digital advertising, public relations and consulting. It employs approximately 108,000 people worldwide, with over 80% of its revenue generated from developed markets, particularly North America and Europe.
Our role in the transaction
Oaklins Intrepid in Los Angeles acted as the exclusive sell-side advisor in this transaction, highlighting the team’s deep domain expertise in the pharmaceutical services sector and broader marketing agency landscape.
Talk to the deal team
Adam Abramowitz
Oaklins Intrepid
Greg Passani
Oaklins Intrepid
Related deals
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreNextalia has acquired a majority stake in Witapp
Nextalia SGR S.p.A. has acquired a majority stake in Witapp S.r.l., an Italian company specializing in software development for the digitization of healthcare infrastructure. The acquisition strengthens Nextalia’s track record in technology companies serving the public sector and supports its strategy of investing in businesses operating at the intersection of healthcare digitization and the modernization of public services.
Learn moreLife & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn more